Statera Biopharma Announces Proposed Underwritten Public Offering
21 Março 2022 - 5:50PM
Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera
Biopharma”), a leading biopharmaceutical company creating
next-generation immune therapies that focus on immune restoration
and homeostasis, today announced it has commenced an underwritten
public offering.
EF Hutton, division of Benchmark Investments,
LLC, is acting as the sole book-running manager for the
offering.
The proposed offering of the units, consisting
of one share of common stock and one warrant to purchase one share
of common stock, and pre-funded units, consisting of one pre-funded
warrant to purchase one share of common stock and one warrant to
purchase one share of common stock, is being offered by the Company
pursuant to a "shelf" registration statement on Form S-3 (File No.
333-238578) filed with the Securities and Exchange Commission (SEC)
and declared effective by the SEC on May 29, 2020, and the
accompanying preliminary prospectus supplement contained
therein.
Anthony L.G., PLLC is acting as legal counsel to
Statera Biopharma, Inc. and Carmel, Milazzo & Feil LLP is
acting as legal counsel to EF Hutton for the offering. Bridgeway
Capital Partners, LLC is acting as the Company’s financial
advisor.
The offering is being made only by means of a
prospectus supplement and accompanying prospectus. A preliminary
prospectus supplement will be filed with the SEC today and a final
prospectus supplement describing the terms of the public offering
will be filed with the SEC and will form a part of the effective
registration statement.
Copies of the preliminary prospectus supplement
and the final prospectus supplement and the accompanying prospectus
relating to this offering may be obtained, when available, on the
SEC’s website at http://www.sec.gov or by contacting EF Hutton,
division of Benchmark Investments, LLC Attention: Syndicate
Department, 590 Madison Avenue, 39th Floor, New York, NY 10022, by
email at syndicate@efhuttongroup.com, or by telephone at (212)
404-7002.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any of the
securities described herein, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Statera Biopharma
Statera Biopharma, Inc. (formerly Cytocom, Inc.)
is a clinical-stage biopharmaceutical company developing novel
immunotherapies targeting autoimmune, neutropenia/anemia, emerging
viruses and cancers based on a proprietary platform designed to
rebalance the body’s immune system and restore homeostasis. Statera
Biopharma has a large platform of toll-like receptor (TLR) agonists
with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod
and GP532. TLRs are a class of protein that plays a key role in the
innate immune system. Statera Biopharma is developing therapies
designed to directly elicit within patients a robust and durable
response of antigen-specific killer T-cells and antibodies, thereby
activating essential immune defenses against autoimmune,
inflammatory, infectious diseases, and cancers. Statera Biopharma
has clinical programs for Crohn’s disease (STAT-201), hematology
(Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205)
in addition to potential expansion into fibromyalgia and multiple
sclerosis. To learn more about Statera Biopharma, please visit
www.staterabiopharma.com.
Forward Looking Statements
This press release contains forward-looking
statements that involve risks and uncertainties. All statements
other than statements of current or historical fact contained in
this press release, including statements regarding the Company’s
expected clinical development timeline for the Company’s product
candidates, future financial position, business strategy, new
products, budgets, liquidity, cash flows, projected costs,
regulatory approvals, the impact of any laws or regulations
applicable to the Company, and plans and objectives of management
for future operations, are forward-looking statements. The words
“anticipate,” “believe,” “continue,” “should,” “estimate,”
“expect,” “intend,” “may,” “plan,” “project,” “will,” and similar
expressions, as they relate to us, are intended to identify
forward-looking statements. We have based these forward-looking
statements on the current expectations about future events held by
management. While we believe these expectations are reasonable,
such forward-looking statements are inherently subject to risks and
uncertainties, many of which are beyond the Company’s control. The
Company’s actual future results may differ materially from those
discussed here for various reasons. The Company discusses many of
these risks under the heading “Risk Factors” in the proxy
statement/prospectus filed with the SEC on June 10, 2021, as
updated by the Company’s other filings with the SEC.
Given these uncertainties, you should not place
undue reliance on these forward-looking statements. The
forward-looking statements included in this press release are made
only as of the date hereof. We do not undertake any obligation to
update any such statements or to publicly announce the results of
any revisions to any of such statements to reflect future events or
developments.
Contacts:Statera
BiopharmaNichol OchsnerExecutive V.P. Investor Relations
and Corporate Communications(732)
754-2545nichol.ochsner@staterabiopharma.com
FINN PartnersGlenn Silver (Media) (973)
818-8198glenn.silver@finnpartners.com
FINN PartnersDavid Carey (IR)(212)
867-1768David.carey@finnpartners.com
Statera BioPharma (NASDAQ:STAB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Statera BioPharma (NASDAQ:STAB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024